Amarogentin, a Secoiridoid Glycoside, Abrogates Platelet Activation through PLCγ2-PKC and MAPK Pathways

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://140.112.115.32:8080/ir/handle/987654321/2765

题名:	Amarogentin, a Secoiridoid Glycoside, Abrogates Platelet Activation through PLCγ2-PKC and MAPK Pathways
作者:	Ting-Lin Yen;Wan-Jung Lu;Li-Ming Lien;Philip Aloysius Thomas;Tzu-Yin Lee;Hou-Chang Chiu;Joen-Rong Sheu;Kuan-Hung Lin
贡献者:	視光學系
日期:	2014-04-01
上传时间:	2025-08-01 15:06:56 (UTC+8)
摘要:	Amarogentin, an active principle of Gentiana lutea, possess antitumorigenic, antidiabetic, and antioxidative properties. Activation of platelets is associated with intravascular thrombosis and cardiovascular diseases. The present study examined the effects of amarogentin on platelet activation. Amarogentin treatment (15~60 μM) inhibited platelet aggregation induced by collagen, but not thrombin, arachidonic acid, and U46619. Amarogentin inhibited collagen-induced phosphorylation of phospholipase C (PLC)γ2, protein kinase C (PKC), and mitogen-activated protein kinases (MAPKs). It also inhibits in vivo thrombus formation in mice. In addition, neither the guanylate cyclase inhibitor ODQ nor the adenylate cyclase inhibitor SQ22536 affected the amarogentin-mediated inhibition of platelet aggregation, which suggests that amarogentin does not regulate the levels of cyclic AMP and cyclic GMP. In conclusion, amarogentin prevents platelet activation through the inhibition of PLCγ2-PKC cascade and MAPK pathway. Our findings suggest that amarogentin may offer therapeutic potential for preventing or treating thromboembolic disorders.
關聯:	BioMed Research International, 2014(1), 728019. https://doi.org/10.1155/2014/728019
显示于类别:	[視光學系] 期刊論文

文件中的档案:

档案	大小	格式	浏览次数
index.html	0Kb	HTML	35	检视/开启

在MMUIR中所有的数据项都受到原著作权保护.

数据加载中.....